source
- Sarepta delays Elevidys study readout while Emergent cuts 90 jobsSarepta Therapeutics told investors that the readout for its non‑ambulatory Elevidys trial will not be available by the end of the year as previously expected. The company indicated the delay durin…
- Podcast explores emerging rapid‑acting and psychedelic therapies for treatment‑resistant depressionIn a recent episode of BioSpace’s Denatured podcast, host Jennifer C. Smith‑Parker talks with Hans Eriksson, chief medical officer of FundaMental Pharma, and Steve Levine, chief patient officer at…